Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The administration of Anamorelin HCl in patients with Non-Small Cell Lung Cancer-Cachexia
(NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.